
Should You Buy The Trade Desk Stock After Its 40% Crash Post-Earnings? Wall Street Says This Will Happen Next.
The Trade Desk stock plummeted nearly 40% following its second-quarter financial report as investors reacted to slowing revenue growth and tariff uncertainty.
The Trade Desk's independent business model has helped the company forge important partnerships across the connected TV and retail advertising landscape.
Wall Street expects adjusted earnings to increase at 14% annually through 2026, which makes the current valuation of 31 times adjusted earnings look tolerable.
10 stocks we like better than The Trade Desk ›
The Trade Desk (NASDAQ: TTD) had its worst day as a public company on Friday, Aug. 8. Shares dropped nearly 40% as investors processed second-quarter financial results, the departure of CFO Alex Kayyal, and a cautious outlook due to tariff uncertainty.
Most Wall Street analysts think the market overreacted. The Trade Desk still has a median target price of $80 per share, which implies 48% upside from its current share price of $54. However, forecasts range from $45 per share at the low end (implying 17% downside) to $135 per share at the high end (implying 150% upside).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Here's what investors should know before buying the post-earnings dip.
The Trade Desk's independence differentiates it from Amazon, Google, and Meta Platforms
The Trade Desk operates the leading independent demand-side platform (DSP), a type of adtech software that helps media buyers plan, measure, and optimize advertising campaigns across digital channels. Its platform leans on artificial intelligence to help clients manage budgets, customize bids, and dynamically target consumers.
The Trade Desk's independence -- meaning it does not own media content that might bias ad spending on its platform -- distinguishes it from larger competitors, such as Alphabet 's Google, Meta Platforms, and Amazon. Those companies have a clear incentive to steer media buyers toward their own ad inventory on websites like Google Search and Instagram, which creates a conflict of interest. In other words, The Trade Desk is more transparent.
The company's independence has allowed it to form a number of critical partnerships. It sources ad inventory from streaming platforms Netflix, Roku, Walt Disney, and Spotify. It sources data from retailers Albertsons, Target, and Walmart. That creates opportunities brands cannot find on other platforms, such that The Trade Desk has become a leader in connected TV (CTV) advertising and a formidable player in retail advertising.
Importantly, the company has consistently taken market share in digital advertising, and CEO Jeff Green believes that trend will continue for the foreseeable future. That sets The Trade Desk up for solid growth in years to come. Adtech spending is projected to increase at 14% annually through 2030, according to Grand View Research.
The Trade Desk reported slowing growth in the second quarter and gave weak guidance that unsettled investors
Despite the sharp decline in the stock, The Trade Desk actually reported reasonably good second-quarter financial results that beat estimates on the top and bottom lines. Revenue rose 19% to $694 million, and non-GAAP (generally accepted accounting principles) net income jumped 5% to $0.41 per diluted share. "With our leadership in CTV as well as other areas such as retail media, digital audio, identity, measurement, and data, we are winning more business," said CEO Jeff Green.
Nevertheless, investors were clearly concerned about slowing growth, particularly because larger competitors delivered stronger results. Meta Platforms and Amazon said advertising revenue increased 21% and 23%, respectively, in the second quarter. The Trade Desk has historically outpaced its largest rivals, so the latest report raises questions about its ability to do so in the future.
That is particularly true because the company provided weak guidance for the third quarter. Management says revenue will increase by 14% to $717 million, and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) will increase 8% to $277 million. But newly appointed CFO Laura Schenkein said actual results could be worse if tariff uncertainty leads to a less favorable economic environment. That gloomy outlook caused the stock to plunge nearly 40% following the report.
Bank of America analyst Jessica Ehrlich downgraded the stock to hold and slashed her target price to $55 per share (down from $130 per share). She still thinks The Trade Desk's revenue will increase at a double-digit pace in the future, but no longer believes a premium valuation is justified because the company is losing momentum. MoffettNathanson also downgraded the stock to sell for similar reasons, slashing its target price to $45 per share.
What Wall Street expects from The Trade Desk in the coming quarters
The Trade Desk's second-quarter report raised questions about its ability to grow revenue faster than 20% annually, and Wall Street analysts are clearly divided on the issue. The company reorganized its sales team earlier this year after missing its own guidance in the fourth quarter for the first time in 33 quarters. Growth could reaccelerate as those changes improve workflows, especially once tariff uncertainty dissipates.
Regardless, Wall Street currently estimates The Trade Desk's adjusted earnings will increase by 14% annually through 2026. That forecast makes the current valuation of 31 times adjusted earnings look tolerable, and it leaves room for upside if the company manages a material reacceleration in sales growth in the future. To that end, patient investors should consider buying the stock on the post-earnings dip.
Should you invest $1,000 in The Trade Desk right now?
Before you buy stock in The Trade Desk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and The Trade Desk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!*
Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 4, 2025
Bank of America is an advertising partner of Motley Fool Money. Trevor Jennewine has positions in Amazon, Roku, and The Trade Desk. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Netflix, Roku, Spotify Technology, Target, The Trade Desk, Walmart, and Walt Disney. The Motley Fool has a disclosure policy.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


National Post
26 minutes ago
- National Post
Michelle Behnke of Boardman Clark in Madison, Wis., Becomes ABA President
Article content TORONTO — Michelle Behnke of Madison, Wisconsin, a lawyer at Boardman Clark, has assumed the role of ABA president for a one-year term concluding in August 2026 at the ABA Annual Meeting in Chicago. Article content 'As we face these seemingly unprecedented times, I am proud to represent the dedicated lawyers of the American Bar Association as their president,' Behnke said. Article content 'As we face these seemingly unprecedented times, I am proud to represent the dedicated lawyers of the American Bar Association as their president,' Behnke said. 'We must be ready to lead and focus on the mission of defending liberty and pursuing justice every day.' Article content Behnke, a practitioner for more than 35 years, officially joined Boardman Clark, one of Madison's largest and longest-standing law firms, last year, focusing on the areas of business, commercial real estate and estate planning. Article content Prior to joining the firm, she was principal of the firm Michelle Behnke & Associates, which she opened in 1998. Her practice dealt with issues of cross-border asset acquisition, real estate refinancing with insurance companies and annexation of property into city limits. Behnke has a long history of service with the ABA. She previously served as ABA treasurer from 2017-2020 and was chair of the ABA Commission on Racial and Ethnic Diversity in the Profession. She has been an instrumental member of the ABA's Strategic Planning Committee and is Wisconsin state chair for the Membership Committee. She was a member of the ABA Board of Governors (2010-2013) and has been a member of the ABA House of Delegates since 2008. She formerly served as chair of the Standing Committee on Bar Activities and Services, and the Standing Committee on Membership. She was also a member of Commission on Governance and a past chair of the Fund for Justice and Education Council. Article content A Madison native, Behnke has been involved in the community since her graduation from the University of Wisconsin (1983) and the University of Wisconsin Law School (1988), serving on nonprofit and corporate boards. She is currently serving on the Board of Directors for the Wisconsin Foundation and Alumni Association and the Law School Board of Visitors. She also serves on the Board of Directors of Capitol Bank and has previously served on the boards of Dean Health Plan, Inc., and SSM Healthcare of Wisconsin. Behnke served as president of the State Bar of Wisconsin from 2004-2005. Article content Behnke has been recognized for her work in the legal profession and her community, receiving the Charles L. Goldberg Distinguished Service Award and the YWCA Women of Distinction Award. In 2015, she was named Real Estate Lawyer of the Year by Best Lawyers in Wisconsin. She also has been listed in both the Best Lawyers in America and Wisconsin Super Lawyers since 2006. Article content The ABA is one of the largest voluntary associations of lawyers in the world. As the national voice of the legal profession, the ABA works to improve the administration of justice, promotes programs that assist lawyers and judges in their work, accredits law schools, provides continuing legal education and works to build public understanding around the world of the importance of the rule of law. View our Article content . Article content Article content Article content Article content Article content Contacts Article content


Globe and Mail
26 minutes ago
- Globe and Mail
The Zacks Analyst Blog Highlights Arista Networks, Hewlett Packard Enterprise and Cisco Systems
For Immediate Release Chicago, IL – August 12, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Arista Networks, Inc. ANET, Hewlett Packard Enterprise Company HPE and Cisco Systems, Inc. CSCO. Here are highlights from Monday's Analyst Blog: Should ANET Stock Be Part of Your Portfolio Post Solid Q2 Earnings? Arista Networks, Inc. reported strong second-quarter 2025 results, with revenues and adjusted earnings soaring year over year, driven by robust demand trends. Innovative product launches and steady customer additions backed by the company's best-in-class portfolio strength led to top-line expansion, while steady margin improvement contributed to earnings growth. Both the bottom and the top lines beat the respective Zacks Consensus Estimate. ANET Rides on Portfolio Strength Arista holds a leadership position in 100-gigabit Ethernet switches for the high-speed data center segment. The company is increasingly gaining market traction in 200- and 400-gig high-performance switching products. In addition, the company offers one of the broadest product lines of data center and campus Ethernet switches and routers in the industry. It provides routing and switching platforms with industry-leading capacity, low latency, port density and power efficiency. The company also innovates in areas such as deep packet buffers, embedded optics and reversible cooling. Arista is witnessing solid demand trends among enterprise customers backed by its multi-domain modern software approach, which is built upon its unique and differentiating foundation, the single EOS (Extensible Operating System) and CloudVision stack. The versatility of Arista's unified software stack across various use cases, including WAN routing and campus and data center infrastructure, has helped it to record steady top-line growth over the years. Cognitive Wi-Fi Software, Cloud Networking Buoy ANET Growth Driven by improved market demand on the back of a flexible business model and solid cash flow, Arista continues to benefit from strong momentum and diversification across its top verticals and product lines. As more business enterprises transition to the cloud, the company is well-positioned for growth in the data-driven cloud networking business with proactive platforms and predictive operations. Arista is also benefiting from the expanding cloud networking market driven by the strong demand for scalable infrastructure. In addition to high capacity and easy availability, its cloud networking solutions promise predictable performance and programmability, enabling integration with third-party applications for network management, automation and orchestration. With customers deploying transformative cloud networking solutions, the company has announced several additions to its multi-cloud and cloud-native software product family with CloudEOS Edge. It has introduced cognitive Wi-Fi software that delivers intelligent application identification, automated troubleshooting and location services. The acquisition of Awake Security has expanded its cognitive campus portfolio with new platforms. These include the 750 Series modular chassis and the 720 Series 96-port fixed switch. Arista has also announced unified edge innovations across wired and wireless networks for its Cognitive Campus Edge portfolio for Enterprise Workspaces and an enterprise-grade Software-as-a-Service offering for the flagship CloudVision platform. ANET Offers Healthy Outlook Arista expects healthy demand trends for the remainder of 2025, backed by the strength of its portfolio and new product introductions. For the third quarter, management expects revenues of approximately $2.25 billion owing to healthy growth momentum and solid demand trends. Non-GAAP gross margin is expected to be 64% and non-GAAP operating margin about 47%. Price Performance Buoyed by a holistic growth model, Arista has surged 64.6% over the past year compared with the industry 's growth of 50.8%. It has also outperformed its peers like Hewlett Packard Enterprise Company and Cisco Systems, Inc.. Hewlett Packard has gained 21.1% and Cisco soared 60.1% during this period. Estimate Revision Trend Earnings estimates for Arista for 2025 have moved up 11 cents to $2.69 over the past seven days, while the same for 2026 has increased 3 cents to $3.00. The positive estimate revision depicts optimism about the stock's growth potential. End Note With solid fundamentals and healthy revenue-generating potential driven by robust demand trends, Arista appears to be a solid investment proposition. Further, a strong emphasis on quality, diligent execution of operational plans and continuous portfolio enhancements are driving more value for customers. Steady improvement in lead times and easing of supply chain woes are major tailwinds. The stock delivered a trailing four-quarter average earnings surprise of 12.8%. Arista currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Riding on a robust earnings surprise history and favorable Zacks Rank, it appears primed for further stock price appreciation. Consequently, investors are likely to profit if they bet on this high-flying stock. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Cisco Systems, Inc. (CSCO): Free Stock Analysis Report Arista Networks, Inc. (ANET): Free Stock Analysis Report


Globe and Mail
26 minutes ago
- Globe and Mail
The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly
For Immediate Release Chicago, IL – August 12, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer PFE, Novo Nordisk NVO and Eli Lilly LLY. Here are highlights from Monday's Analyst Blog: Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results? Pfizer announced strong second-quarter 2025 results on Aug. 5, beating estimates for both earnings and sales. Adjusted EPS of 78 cents rose 30% year over year while revenues of $14.7 billion were up 10%. Revenues from the Vyndaqel family, Padcev, Lorbrena, Paxlovid and Comirnaty vaccine rose in the quarter. Sales of some other key products like Prevnar, Xeljanz, and Eliquis also improved from first-quarter levels, partially offset by a decline in Ibrance. However, higher manufacturer discounts resulting from the Medicare Part D redesign under the Inflation Reduction Act (IRA) hurt U.S. revenues by $875 million. Pfizer reaffirmed its outlook for revenues for 2025. However, the company raised its adjusted EPS guidance range, despite including a one-time charge related to the 3SBIO transaction. However, a single quarter's results are not so important for long-term investors, and the focus should rather be on the company's strong fundamentals. Let's understand the company's strengths and weaknesses to better analyze how to play Pfizer stock in the post-earnings scenario. PFE Enjoys a Strong Position in Oncology Pfizer is one of the largest and most successful drugmakers in oncology. The addition of Seagen strengthened its position in oncology. Its oncology revenues are rising, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Its oncology revenues grew 9% in the first half of 2025 Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. In July, it closed a global ex-China in-licensing agreement with China's 3SBio for exclusive rights to the latter's dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline. Pfizer is also working on expanding the labels of approved products (oncology as well as non-oncology) like Padcev, Adcetris, Litfulo, Nurtec, Velsipity and Elrexfio, among others. PFE's New Drugs & Seagen Acquisition Driving Top-Line Growth Pfizer's non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen (December 2023). Pfizer's recently launched and acquired products delivered $4.7 billion in revenues in the first half of 2025, rising approximately 15% operationally versus last year. Continued growth of Pfizer's diversified portfolio of drugs, particularly oncology, should support top-line growth in 2025. Pfizer's new products/late-stage pipeline candidates and newly acquired products, including those acquired from Seagen, position it strongly for operational growth in 2025 and beyond. Pfizer expects the 2025 to 2030 revenue CAGR to be approximately 6%. Pfizer expects the acquisition of Seagen to contribute more than $10 billion in 2030 risk-adjusted revenues with potential significant growth beyond 2030. Uncertainty Related to Sales of COVID Products With the end of the pandemic, sales of Pfizer's COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 from $56.7 billion in 2022. Though sales of Paxlovid and Comirnaty have stabilized in 2025 after declining significantly in the past two years, their sales are usually weighted toward the second half of the year and are difficult to estimate as they depend on infection rates. There is an element of uncertainty related to COVID sales and they may decline further in future years. Other Headwinds in 2025 Though Pfizer expects a moderate negative impact on revenues from the loss of exclusivity in 2025, the impact is expected to be significant in the 2026-2030 period as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, will face patent expirations. Pfizer expects an unfavorable impact of approximately $1 billion from the Medicare Part D redesign under the IRA, which took effect in the first quarter of 2025. Higher-priced drugs, including Vyndaqel, Ibrance, Xtandi and Xeljanz, are expected to be most affected by the IRA. In April, Pfizer said it is discontinuing the development of its GLP-1R agonist, danuglipron, which was developed as a weight loss pill. Pfizer took the decision after one of the participants in the dose-optimization studies developed a potentially drug-induced liver injury, which resolved after danuglipron was discontinued. Novo Nordisk and Eli Lilly currently dominate the obesity market with their GLP-1 injections. The uncertainty around tariffs and trade production measures has muted economic growth. President Trump has once again threatened to impose heavy tariffs, as high as 250%, on pharmaceutical imports. Trump's repeated threats to impose tariffs on pharmaceutical imports are aimed at pushing American pharma companies to shift pharmaceutical production back to the United States, primarily from European and Asian countries. Trump has said that drugmakers have about one to one and a half years to bring production back to the United States before the new tariffs are imposed. On the Q2 conference call, Pfizer's chief financial officer (CFO), David Denton, said that the company is prepared to mitigate the impact of tariffs in the short term while plans are being devised to help mitigate the potential long-term impact of tariffs on its business operations. President Trump is also trying to implement the Most Favored Nation (MFN) pricing policy. The goal of this proposed policy is to ensure that U.S. consumers pay the same price for some prescription drugs as the nation that pays the lowest price for that drug. Such a policy, if implemented, can hurt prices and reimbursement of some of the company's drugs. PFE's Stock Price, Estimates & Valuation Pfizer's stock has declined 2.4% so far this year compared with a decrease of 6.8% for the industry. From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 7.93 forward earnings, lower than 13.71 for the industry and the stock's 5-year mean of 10.80. The stock is also much cheaper than other large drugmakers like AbbVie, Novo Nordisk, Lilly, AstraZeneca, J&J and others. The Zacks Consensus Estimate for earnings has risen from $3.07 per share to $3.11 per share for 2025, while that for 2026 has increased from $3.06 per share to $3.09 per share over the past seven days. Stay Invested in PFE Stock Pfizer faces its share of challenges, including COVID-19 product-related uncertainty, U.S. Medicare Part D headwinds, the upcoming loss of exclusivity (LOE) cliff in the 2026-2030 period, uncertainties around tariffs and a volatile macro environment. However, with COVID-related uncertainties diminishing, its revenue volatility is declining. Pfizer's key drugs like Vyndaqel, Padcev and its recently launched and acquired products should help the company largely offset its LOEs over the next several years. Pfizer expects cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027. Pfizer's significant cost reduction and efforts to improve R&D productivity measures should drive profit growth. Though Pfizer does not expect strong top-line growth over the next three years due to the LOEs, it expects EPS growth. Pfizer's dividend yield stands at around 7%, which is impressive. In the first half of 2025, Pfizer returned $4.9 billion to shareholders via our quarterly dividend. Investors should continue to retain this Zacks Rank #3 (Hold) stock in their portfolio as it appears to have significant upside potential. It will be a great pick for value investors, considering its cheap valuation, and for income investors due to its high dividend yield. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Pfizer Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report